The rising use of GLP-1 agonists to help manage the obesity epidemic is not only reshaping how consumers taking the ...

Dispensations of tirzepatide and semaglutide increased significantly in recent years while the use of other glucose-lowering ...

chronic kidney disease, or sarcopenia/frailty, particularly those who have experienced an inflammatory acute medical event such as a fall or bone fracture and are on GLP-1 medications. According to ...

As the FDA cracks down on compounded GLP-1 drugs like semaglutide and tirzepatide, the market for GLP-1 supplements is taking ...

Taking the drug made one writer feel so sick she quit and focused on healthy habits instead of her body size. Turns out, 65% ...

Pfizer and Eli Lilly reporting significant - and opposing - news in the GLP-1 industry Lexaria's technology ... owned by Novo Nordisk®, to "reduce the risk of kidney disease worsening, kidney ...

A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the ... It has also been shown to reduce kidney disease-related events in people with type 2 diabetes ...

Novo Nordisk has abandoned a drug it licensed from KBP Biosciences last year in a deal valued at up to $1.3 billion ... its GLP-1-based therapies for reducing cardiovascular risk and kidney ...